Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

“Herbal” or “natural Viagra” is a name given to a variety of supplements by their manufacturers. They’re sold for the purpose of improving erectile function or sexual desire in people ...

Roman sells both generic Viagra and brand-name Viagra, and they’re available in 25-, 50-, and 100-mg tablets. One benefit of using Roman is the variety of additional ED medications available ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

As one of the largest vaccine makers, Pfizer has a big part of its business hinging on potential immunization policy changes under the incoming Trump administration. So when vaccine skeptic Robert F.

Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits. The New York pharmaceutical giant Tuesday said it ...

Pfizer CEO met RFK Jr. and Trump, developed good relationship Trump committed to reforming pharmacy benefit managers, reducing medicine costs Pfizer faces investor pressure over strategy, shares ...

Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share ...